Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

13 matching registry records; showing 13 on this page, newest registry updates first. Search checked 2026-10-07 18:06 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4RecruitingINTERVENTIONAL

Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes

ClinicalTrials.gov · NCT07558863 · Registry updated: 2026-04-30

Condition / research focus: Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2026-04-01. Completion: 2028-08-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 Receptor Agonists (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

ClinicalTrials.gov · NCT05172999 · Registry updated: 2026-03-13

Condition / research focus: Atypical Endometrial Hyperplasia; Obesity; Fertility Issues
Sponsor: Fudan University
Countries with listed sites: China
Registry dates and results: Start: 2022-01-08. Completion: 2026-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

levonorgestrel-releasing intrauterine system (device) — also listed as: MIRENA
Polyethylene Glycol Loxenatide (drug) — also listed as: Fulaimei, PEX168

Where the study takes place — 1 listed sites

Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients

ClinicalTrials.gov · NCT06217887 · Registry updated: 2024-01-23

Condition / research focus: Type 2 Diabetes Mellitus; Cognitive Function Abnormal
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Countries with listed sites: China
Registry dates and results: Start: 2020-05-10. Completion: 2024-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

loxenatide Group (drug) — also listed as: metformin
Gliclazide Group (drug) — also listed as: metformin

Where the study takes place — 1 listed sites

Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects

ClinicalTrials.gov · NCT02447601 · Registry updated: 2017-01-24

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2015-03-30. Completion: 2015-08-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide
Simvastatin (drug) — also listed as: Shujiangzhi

Where the study takes place — 1 listed sites

Shanghai Mental Health Center (SMHC)
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

ClinicalTrials.gov · NCT02477969 · Registry updated: 2017-01-24

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2014-02-27. Completion: 2017-06 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168(100µg) (drug) — also listed as: Polyethylene Glycol Loxenatide
PEX168(200µg) (drug) — also listed as: Polyethylene Glycol Loxenatide
Placebo (drug) — also listed as: PEGylated Loxenatide Injection Mimetics
Metformin (drug) — also listed as: ge hua zhi

Where the study takes place — 1 listed sites

Shanghai sixth People's Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients

ClinicalTrials.gov · NCT02477865 · Registry updated: 2017-01-24

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: No country reported
Registry dates and results: Start: 2014-03-23. Completion: 2017-02 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168(100µg) (drug) — also listed as: Polyethylene Glycol Loxenatide
PEX168(200µg) (drug) — also listed as: Polyethylene Glycol Loxenatide
Placebo (drug) — also listed as: Injection mimetic

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

ClinicalTrials.gov · NCT02472236 · Registry updated: 2017-01-24

Condition / research focus: Healthy
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2015-06-08. Completion: 2016-01-18 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide
Digoxin (drug) — also listed as: Digaoxin tablet

Where the study takes place — 1 listed sites

The first affiliate of Xi'an Jiaotong University
Xi’an, Shanxi, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

ClinicalTrials.gov · NCT02461914 · Registry updated: 2017-01-24

Condition / research focus: Healthy
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-08-01. Completion: 2016-07-13 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide
Warfarin (drug) — also listed as: Warfarin sodium tablets

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects

ClinicalTrials.gov · NCT02451527 · Registry updated: 2016-11-30

Condition / research focus: Healthy
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Countries with listed sites: China
Registry dates and results: Start: 2015-05. Completion: 2016-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Digoxin (drug) — also listed as: Digoxine, Digoxinum, Lanoxin, Vanoxin
PEX168 (drug) — also listed as: Polythylene Glycol Loxenatide Injection

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function

ClinicalTrials.gov · NCT02467790 · Registry updated: 2016-01-26

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2015-02. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide

Where the study takes place — 1 listed sites

Third Xiangya Hospital, Central South Univety
Changsha, Hunan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT01976858 · Registry updated: 2013-11-06

Condition / research focus: Type 2 Diabetes
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2011-06. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide

Where the study takes place — 1 listed sites

Beijing tongren hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT01965496 · Registry updated: 2013-10-18

Condition / research focus: Type 2 Diabetes
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2012-03. Completion: 2013-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide

Where the study takes place — 1 listed sites

People's Liberation Army General Hospital of Chengdu Military Region
Chengdu, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT01965509 · Registry updated: 2013-10-18

Condition / research focus: Type 2 Diabetes
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2012-05. Completion: 2013-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 or placebo (drug) — also listed as: Polyethylene Glycol Loxenatide or Placebo

Where the study takes place — 1 listed sites

China-Japan Friendship Hospital
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

13 matching registry records; showing 13 on this page, newest registry updates first. Search checked 2026-10-07 18:06 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4RecruitingINTERVENTIONAL

Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes

ClinicalTrials.gov · NCT07558863 · Registry updated: 2026-04-30

Condition / research focus: Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2026-04-01. Completion: 2028-08-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 Receptor Agonists (drug)

Where the study takes place — 1 listed sites

the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

ClinicalTrials.gov · NCT05172999 · Registry updated: 2026-03-13

Condition / research focus: Atypical Endometrial Hyperplasia; Obesity; Fertility Issues
Sponsor: Fudan University
Countries with listed sites: China
Registry dates and results: Start: 2022-01-08. Completion: 2026-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

levonorgestrel-releasing intrauterine system (device) — also listed as: MIRENA
Polyethylene Glycol Loxenatide (drug) — also listed as: Fulaimei, PEX168

Where the study takes place — 1 listed sites

Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients

ClinicalTrials.gov · NCT06217887 · Registry updated: 2024-01-23

Condition / research focus: Type 2 Diabetes Mellitus; Cognitive Function Abnormal
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Countries with listed sites: China
Registry dates and results: Start: 2020-05-10. Completion: 2024-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

loxenatide Group (drug) — also listed as: metformin
Gliclazide Group (drug) — also listed as: metformin

Where the study takes place — 1 listed sites

Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects

ClinicalTrials.gov · NCT02447601 · Registry updated: 2017-01-24

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2015-03-30. Completion: 2015-08-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide
Simvastatin (drug) — also listed as: Shujiangzhi

Where the study takes place — 1 listed sites

Shanghai Mental Health Center (SMHC)
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

ClinicalTrials.gov · NCT02477969 · Registry updated: 2017-01-24

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2014-02-27. Completion: 2017-06 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168(100µg) (drug) — also listed as: Polyethylene Glycol Loxenatide
PEX168(200µg) (drug) — also listed as: Polyethylene Glycol Loxenatide
Placebo (drug) — also listed as: PEGylated Loxenatide Injection Mimetics
Metformin (drug) — also listed as: ge hua zhi

Where the study takes place — 1 listed sites

Shanghai sixth People's Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients

ClinicalTrials.gov · NCT02477865 · Registry updated: 2017-01-24

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: No country reported
Registry dates and results: Start: 2014-03-23. Completion: 2017-02 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168(100µg) (drug) — also listed as: Polyethylene Glycol Loxenatide
PEX168(200µg) (drug) — also listed as: Polyethylene Glycol Loxenatide
Placebo (drug) — also listed as: Injection mimetic

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

ClinicalTrials.gov · NCT02472236 · Registry updated: 2017-01-24

Condition / research focus: Healthy
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2015-06-08. Completion: 2016-01-18 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide
Digoxin (drug) — also listed as: Digaoxin tablet

Where the study takes place — 1 listed sites

The first affiliate of Xi'an Jiaotong University
Xi’an, Shanxi, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

ClinicalTrials.gov · NCT02461914 · Registry updated: 2017-01-24

Condition / research focus: Healthy
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-08-01. Completion: 2016-07-13 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide
Warfarin (drug) — also listed as: Warfarin sodium tablets

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects

ClinicalTrials.gov · NCT02451527 · Registry updated: 2016-11-30

Condition / research focus: Healthy
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Countries with listed sites: China
Registry dates and results: Start: 2015-05. Completion: 2016-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Digoxin (drug) — also listed as: Digoxine, Digoxinum, Lanoxin, Vanoxin
PEX168 (drug) — also listed as: Polythylene Glycol Loxenatide Injection

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function

ClinicalTrials.gov · NCT02467790 · Registry updated: 2016-01-26

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2015-02. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide

Where the study takes place — 1 listed sites

Third Xiangya Hospital, Central South Univety
Changsha, Hunan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT01976858 · Registry updated: 2013-11-06

Condition / research focus: Type 2 Diabetes
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2011-06. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide

Where the study takes place — 1 listed sites

Beijing tongren hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT01965496 · Registry updated: 2013-10-18

Condition / research focus: Type 2 Diabetes
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2012-03. Completion: 2013-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 (drug) — also listed as: Polyethylene Glycol Loxenatide

Where the study takes place — 1 listed sites

People's Liberation Army General Hospital of Chengdu Military Region
Chengdu, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT01965509 · Registry updated: 2013-10-18

Condition / research focus: Type 2 Diabetes
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2012-05. Completion: 2013-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEX168 or placebo (drug) — also listed as: Polyethylene Glycol Loxenatide or Placebo

Where the study takes place — 1 listed sites

China-Japan Friendship Hospital
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →